Sarah Austin

Mrs. Sarah Austin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2022 in Journal of Genetic Counseling
Verified
Journal Article
Open access
KRKen Resnicow
Ken Resnicow
EDEmerson Delacroix
Emerson Delacroix
GCGabriela Chen
Gabriela Chen
SASarah Austin
Sarah Austin
ESElena Stoffel
Elena Stoffel
DCDeborah Cragun
Deborah Cragun
Genetic counselors (GCs) have traditionally been trained to adopt a position of equipoise or clinical neutrality. They provide information, answer questions, address barriers, and engage in shared decision‐making, but generally, they do not prescribe a genetic test. Historically, GCs have generally been trained not to persuade the ambivalent or resistant patient. More recently, however, there has been discussion regarding when a greater degree of persuasion or directionality may be appropriate within genetic counseling (GC) and what role MI may play in this process. The role for “persuasive GC” is based on the premise that some genetic tests provide actionable information that would clearly benefit patients and families by impacting treatment or surveillance. For other tests, the benefits are less clear as they do not directly impact patient care or the benefits may be more subjective in nature, driven by patient values or psychological needs. For the former, we propose that GCs may adopt a more persuasive clinical approach while for the latter, a more traditional equipoise stance may be more appropriate. We suggest that motivational interviewing (MI) could serve as a unifying counseling model that allows GCs to handle both persuasive and equipoise encounters. For clearly beneficial tests, while directional, the MI encounter can still be non‐directive, autonomy‐supportive, and patient‐centered. MI can also be adapted for equipoise situations, for example, placing less emphasis on eliciting and strengthening change talk as that is more a behavior change strategy than a shared decision‐making strategy. The core principles and strategies of MI, such as autonomy support, evocation, open questions, reflective listening, and affirmation would apply to both persuasive and equipoise encounters. Key issues that merit discussion include how best to train GCs both during their initial and post‐graduate education.

27 May 2024 in Journal of Genetic Counseling
Verified
Journal Article
Open access
SASarah Austin
Sarah Austin
EHErika N. Hanson
Erika N. Hanson
EDEmerson Delacroix
Emerson Delacroix
EBElizabeth Bacon
Elizabeth Bacon
JRJohn Rice
John Rice
KRKen Resnicow
Ken Resnicow
Genetic testing for hereditary cancer syndromes can provide lifesaving information allowing for individualized cancer screening, prevention, and treatment. However, the determinants, both barriers and motivators, of genetic testing intention are not well described. A survey of barriers and motivators to genetic testing was emailed to adult patients eligible for genetic testing based on cancer diagnosis who previously have not had genetic testing (n = 201). Associations between barriers/motivators with testing intention and confidence were examined first by correlation followed by multivariable linear regression model holding constant potential covariates. Seven barrier items from two domains (logistics and genetic testing knowledge) were found to significantly negatively correlate with genetic testing intention. Unexpectedly, three barrier items had significant positive correlation with genetic testing intention; these were related to family worry (passing a condition on to future generations) and testing knowledge (needing more information on the genetic testing process and what it has to offer). Ten barrier items had significant negative correlation with confidence to get a genetic test and encompassed four domains: stigma, insurance/genetic discrimination, knowledge, and cost. All motivator items were associated with intention to get a genetic test, while none were associated with confidence. Multivariable analysis yielded six total barriers (five from the knowledge domain, one from cost domain) and two motivators (relieved to know and treatment impact) that were significantly associated with genetic testing intention or confidence when controlling for demographic characteristics. These findings indicate the need for tailored interventions to amplify motivating factors and counter‐message barriers to enhance patient motivation and confidence to undergo testing.

1 March 2024 in JCO Precision Oncology
Verified
Journal Article
Closed access
MJMichelle F. Jacobs
Michelle F. Jacobs
JGJoshua W. Goldman
Joshua W. Goldman
SASarah Austin
Sarah Austin
EKErika S. Koeppe
Erika S. Koeppe
AMAndrea M. Murad
Andrea M. Murad
RMRajen J. Mody
Rajen J. Mody
PURPOSE: Paired tumor-germline sequencing can identify somatic variants for targeted therapy and germline pathogenic variants (GPVs) causative of hereditary cancer/tumor predisposition syndromes. It is unknown how patients/families in pediatric oncology use information about an identified GPV. We assessed recall of germline results and actions taken on the basis of findings. METHODS: We completed phone surveys with patients (and/or their parent) with GPVs identified via a single academic medical center's paired tumor-germline sequencing study. Seven hundred forty pediatric (aged 0-25 years) oncology patients were enrolled in this sequencing study between May 2012 and August 2021. Ninety-six participants (13.0%) had at least one GPV identified and were therefore eligible for this survey. The parent/guardian (for patients younger than 18 years or deceased patients) or patients themselves (if 18 years or older) were contacted. Survey topics included germline result recall, experience with genetic counseling, changes to patient's cancer treatment/screening, sharing of results with family members, and lifestyle changes. RESULTS: Fifty-three surveys (response rate, 55.2%) were completed between October 2021 and June 2022. Thirty-seven (69.8%) respondents correctly recalled the identified GPV. Discussing results with a genetic counselor ( P = .0001), having a GPV related to the cancer/tumor diagnosis ( P = .002), and non-Hispanic White race/ethnicity ( P = .02) were associated with accurate recall. Twenty-five respondents (47.2%) reported a change in the child's cancer treatment and/or screening recommendations, 17 respondents (32.1%) made a lifestyle change on the basis of the results, and 44 respondents (83.0%) shared results with at least one family member. CONCLUSION: While most respondents remembered that a GPV was identified in the patient, some did not recall having a GPV found, and others recalled germline findings incorrectly. Future work may determine patient/family preferences for timing/method of result return to optimize patient recall and use of germline results.

14 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EDEmerson Delacroix
Emerson Delacroix
SASarah Austin
Sarah Austin
JRJohn D. Rice
John D. Rice
ESElena Martinez Stoffel
Elena Martinez Stoffel
EKErika Koeppe
Erika Koeppe
KRKen Resnicow
Ken Resnicow
Background: Despite clinical utility in managing hereditary cancers, genetic testing (GT) remains underutilized. While barriers include knowledge gaps and cost, clinician recommendation is a major driver of GT uptake, with rates varying by cancer type and family cancer history documentation. Methods: Adult participants (≥18 years) were recruited through multiple sources to complete a cancer family history survey for a larger intervention trial. Participants with personal or family history indicating increased hereditary cancer risk who had not undergone GT (N = 3001) were invited to complete a baseline survey. Multivariable logistic regression was used to analyze associations between demographics and cancer history by receipt of a clinician recommendation for GT. Results: Among 784 respondents, most were White (84.6%), female (58.4%), and over age 51 (75.3%), with 58.2% reporting a diagnosis of cancer. Only 14.0% reported receiving a clinician recommendation for GT, with lower recommendation rates among younger adults (20.1%), those reporting no financial stress (10.7%), and those with higher education (12.0%). Multivariate analysis showed participants who did not report financial stress (p = 0.049) were less likely to receive a recommendation. Discussion: These findings highlight disparities in GT recommendation by clinicians. Increased clinician education about indications for GT, the implementation of electronic medical record tools to facilitate the identification of patients with guideline-concordant personal and/or biological-relative cancer history, and patient-facing interventions could standardize the dissemination of recommendations for GT. Conclusions: Future efforts that focus on increasing clinician education and electronic decision support should identify individuals with personal and/or biological-relative cancer history meeting criteria for GT.

15 October 2025 in Journal of Genetic Counseling
Verified
Journal Article
Open access
SASarah Austin
Sarah Austin
EDEmerson Delacroix
Emerson Delacroix
JRJohn D. Rice
John D. Rice
EKErika Koeppe
Erika Koeppe
ESElena M. Stoffel
Elena M. Stoffel
KRKenneth Resnicow
Kenneth Resnicow
Genetic testing for hereditary cancer syndromes can provide lifesaving information allowing for individualized cancer screening, prevention, and treatment. A broader understanding of how psychosocial factors impact motivation to undergo genetic testing is needed to improve uptake among individuals who would benefit from testing. Adults (≥18 years) who met criteria for genetic testing based on a self‐reported family cancer history and had not previously completed testing were invited to complete a survey ( n = 799) assessing psychosocial factors including barriers to genetic testing, healthcare distrust, perceived self‐efficacy, clinician autonomy support, and genetic testing knowledge. Associations between these psychosocial factors and testing motivation were examined first by correlation followed by multivariable linear regression. Self‐efficacy had a significant positive correlation with genetic testing motivation, while barriers and healthcare distrust were negatively correlated with motivation. In an adjusted multivariable regression model, higher self‐efficacy was associated with higher motivation while higher barriers and healthcare distrust were negatively associated with genetic testing motivation. Individuals of older age (51+), non‐White race, and lower perceived socioeconomic status reported higher mean motivation scores. The negative association between distrust and barriers with genetic testing intention may be a potential target for tailored interventions for genetic testing.

1 December 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
MJMichelle F. Jacobs
Michelle F. Jacobs
SASarah Austin
Sarah Austin
AMAndrea M. Murad
Andrea M. Murad
EKErika Koeppe
Erika Koeppe
CKChandan Kumar-Sinha
Chandan Kumar-Sinha
RMRajen J. Mody
Rajen J. Mody
PURPOSE: Cancer predisposition syndromes caused by germline pathogenic variants (GPV) in adult-onset cancer predisposition genes (aoCPG) are those for which there is low risk of cancer in children, with genetic testing and screening for these conditions typically deferred until adulthood. GPV in aoCPG have been identified in pediatric oncology patients, but in these cases the potential contribution of the aoCPG to cancer development is often unknown. We investigated the role GPV in aoCPG may play in childhood cancer development. METHODS: Results of paired tumor-germline sequencing from pediatric oncology patients enrolled from May 2012 to October 2023 were analyzed for frequency of GPV in aoCPG. Germline testing included analysis of up to 182 cancer predisposition genes. Tumor loss-of-heterozygosity, presence of second somatic pathogenic variant, immunohistochemical stain for protein expression, and/or tumor mutation burden were used to determine possible causation. RESULTS: Of the 954 participants, 42 (4.4%) had GPV in aoCPG. Six (14.3%) of these 42 participants had tumor findings indicating their GPV in an aoCPG likely contributed to cancer development: three patients with Lynch syndrome (two anaplastic astrocytomas, one giant cell glioblastoma) and one each with GPV in ATM (craniopharyngioma and diffuse high-grade glioma), BRIP1 (atypical teratoid rhabdoid tumor), and CHEK2 (mixed germ cell tumor of pineal gland). CONCLUSION: These findings contribute to the literature suggesting that, rarely, GPV in aoCPG may contribute to cancer diagnoses in children, raising the question of how tumors in these cases may present differently in children than adults. Increased knowledge about potential childhood cancer risks related to what have historically been considered aoCPG could modify predictive genetic testing recommendations for children and enhance existing cancer screening protocols.